- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | PEGBIO CO-B (02565): FORM OF PROXY FOR USE AT THE 2026 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON THURSDAY, NOVEMBER 12, 2026 | 1 | HKEx | ||
| Fr | PEGBIO CO-B (02565): NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| Fr | PEGBIO CO-B (02565): (1) PROPOSED REMOVAL OF AUDITOR (2) PROPOSED APPOINTMENT OF AUDITOR (3) PROPOSED CHANGE IN USE OF PROCEEDS FROM THE GLOBAL OFFERING ... | - | HKEx | ||
| 23.09. | PEGBIO CO-B (02565): 2026 INTERIM REPORT | - | HKEx | ||
| 18.09. | PEGBIO CO-B (02565): CHANGE IN USE OF PROCEEDS FROM THE GLOBAL OFFERING | 1 | HKEx | ||
| 18.09. | PEGBIO CO-B (02565): PROPOSED CHANGE OF AUDITOR | - | HKEx | ||
| 02.09. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT JOINT R&D COLLABORATION WITH SN BIOSCIENCE ADVANCING THE LONG-ACTING DEVELOPMENT OF THREE NEXT-GENERATION ... | - | HKEx | ||
| 25.08. | PEGBIO CO-B (02565): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| PEGBIO Aktie jetzt für 0€ handeln | |||||
| 13.08. | Lexaria geht Partnerschaft mit PegBio zur Verabreichung von GLP-1-Wirkstoffen ein | 6 | Investing.com Deutsch | ||
| 13.08. | Lexaria enters partnership with PegBio for GLP-1 drug delivery | 3 | Investing.com | ||
| 13.08. | Lexaria Bioscience Corp.: Lexaria Enters a Material Transfer Agreement With PegBio | 441 | ACCESS Newswire | KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into... ► Artikel lesen | |
| 13.08. | PEGBIO CO-B (02565): DATE OF BOARD MEETING | - | HKEx | ||
| 22.07. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT ISSUANCE OF THE FIRST BATCH OF COMMERCIAL PRESCRIPTIONS OF PAIDAKANG NATIONWIDE AND SATISFACTION OF THE CONDITIONS ... | - | HKEx | ||
| 10.07. | China's PegBio Pops on Deal to Develop Oral Formulations for Obesity, Metabolic Drugs With US' Rani Therapeutics | 2 | Yicai Global | ||
| 10.07. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT COLLABORATION WITH NASDAQ-LISTED RANI THERAPEUTICS TO ADVANCE ORAL DELIVERY OF MULTIPLE INNOVATIVE METABOLIC ... | 3 | HKEx | ||
| 09.07. | Rani Therapeutics partners with PegBio on obesity drugs | 1 | Investing.com | ||
| 09.07. | Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates | 227 | GlobeNewswire (Europe) | ~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~ ~ Agreement expands Rani's obesity... ► Artikel lesen | |
| 29.06. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT CORE PRODUCT VISEPEGENATIDE INJECTION PASSED THE PRELIMINARY REVIEW IN ACCORDANCE WITH THE 2026 NATIONAL REIMBURSEMENT ... | - | HKEx | ||
| 26.06. | PEGBIO CO-B (02565): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 26.06. | PEGBIO CO-B (02565): COMPLETION OF THE H SHARE FULL CIRCULATION | 1 | HKEx |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,100 | 0,00 % | Börsenschluss: Sell on Good News - Qiagen springt, AI-Werte brechen ein | Gute Zahlen, fallende Kurse: Am Donnerstag dominierten an der Börse Frankfurt Gewinnmitnahmen. Selbst überzeugende Quartalsberichte lockten kaum noch Käufer an - das Muster "Sell on Good News" setzte... ► Artikel lesen | |
| BICARA THERAPEUTICS | 10,080 | -42,40 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth | President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 22,950 | -16,67 % | Rapport Therapeutics bricht ein: Großvolumige Kapitalerhöhung mit hohem Abschlag belastet Kurs | ||
| BEAM THERAPEUTICS | 27,960 | +12,24 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| PRIME MEDICINE | 5,240 | +20,32 % | Prime Medicine, Inc.: Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease | -- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,335 | +7,04 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| INHIBRX BIOSCIENCES | 70,26 | -26,55 % | Inhibrx Biosciences, Inc.: Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study | First OX40 agonist to demonstrate clinical benefit in a randomized study
INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 40,050 | +1,37 % | Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 | - Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% -
- EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human... ► Artikel lesen | |
| MODERNA | 191,64 | +3,40 % | Nachdem neue Studiendaten von Moderna durchsickerten, erlebt die Aktie heftige Verluste, obwohl die Eckpunkte eigentlich positiv klingen | Eigentlich wollte Moderna erst am Wochenende neue Ergebnisse zu einer Studie um personalisierte Krebsimpfstoffe veröffentlichen. Teile davon fanden jedoch schon vorher ihren Weg ins Netz, woraufhin... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 92,60 | +4,00 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| TANGO THERAPEUTICS | 23,215 | +1,42 % | Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside? | ||
| ABSCI | 11,570 | +9,46 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 278,95 | +4,25 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 31,710 | +0,16 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints Rob Scott, MD to Board of Directors | ||
| MINERALYS THERAPEUTICS | 21,050 | -0,38 % | Mineralys reports positive phase 2 CKD trial results |
PEGBIO CO LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PEGBIO CO LTD finden Sie auf Wallstreet Online.